Stem Cell + Treg Therapy for Kidney Transplant

This trial tests a new method to assist kidney transplant recipients. It combines donor hematopoietic stem cells and recipient Tregs to determine if patients can eventually discontinue anti-rejection drugs. The trial targets individuals with a living donor and a compatible match. Participants should be comfortable with cell infusion treatments and agree to follow specific post-transplant guidelines. This trial does not suit individuals with previous transplants or certain health conditions, such as HIV. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative therapy.

Research has shown that using donor stem cells (special cells that can turn into different types of blood cells) in kidney transplants yields promising results. Some studies have reported stable kidney function and low rejection rates. However, long-term effects can vary, and some risks, such as ongoing issues, may develop over time.

Regarding regulatory T cells (a type of immune cell that helps control the body's immune response), studies have shown they are generally well-tolerated in kidney transplant patients. Reports indicate no major side effects or rejection events related to their use.

Unlike the standard of care for kidney transplants, which often relies on lifelong immunosuppressive drugs, this new treatment uses an infusion of donor hematopoietic stem cells combined with regulatory T cells (Tregs). Researchers are excited because this approach aims to promote immune tolerance, potentially reducing or even eliminating the need for long-term immunosuppression. The inclusion of Tregs also offers a unique mechanism that might enhance the body’s acceptance of the new kidney, minimizing rejection risks. This innovative strategy could lead to better outcomes and fewer side effects for transplant recipients.

Research has shown that using donor stem cells can improve kidney transplant success. In a study with nine patients, this treatment led to important changes in proteins, helping the body accept the new kidney. Early results from another study showed that some patients could stop taking anti-rejection drugs after receiving donor stem cells. In this trial, participants will receive a combined treatment of donor stem cells and recipient Tregs. Studies indicate that regulatory T cells (Tregs) help maintain kidney function and prevent rejection. In one trial, patients who received Treg therapy all survived without any rejection issues. Together, these treatments show promise in reducing the need for long-term medication to prevent organ rejection after kidney transplants.¹²⁴⁶⁷